Efficacy of brachytherapy for prostate cancer in African Americans compared with Caucasians

Brachytherapy

Volumn 3, Issue 1, 2004, Pages 30-33

  Barrett, William L ^a   Kassing, William M ^a   Shirazi, Reza ^a  

^a UNIVERSITY OF CINCINNATI   (United States)

Author keywords

African Americans and Caucasians; Biochemical response; Prostate brachytherapy

Indexed keywords

IODINE 125; PROSTATE SPECIFIC ANTIGEN;

AFRICAN AMERICAN; ARTICLE; BIOCHEMISTRY; BRACHYTHERAPY; CANCER RECURRENCE; CONTROLLED STUDY; EUROPEAN AMERICAN; HUMAN; MAJOR CLINICAL STUDY; MALE; PALPATION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; RACE DIFFERENCE; RADIATION RESPONSE; TREATMENT OUTCOME;

ADENOCARCINOMA; AFRICAN AMERICANS; BRACHYTHERAPY; EUROPEAN CONTINENTAL ANCESTRY GROUP; HUMANS; IODINE RADIOISOTOPES; MALE; NEOPLASM RECURRENCE, LOCAL; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 1942478650     PISSN: 15384721     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brachy.2003.11.003     Document Type: Article

References (17)

1. Greenlee R.T., Murray T., Bolden S., et al. Cancer statistics, 2000. CA Cancer J Clin. 50:2000;7-33.
2. Natarajan N., Murphy G.P., Mettlin C. Prostate cancer in blacks: An update from the American College of Surgeons patterns of care studies. J Surg Oncol. 40:1989;232-236.
3. Roach M.D., Krall J., Keller J.W., et al. The prognostic significance of race and survival from prostate cancer based on patients irradiated on Radiation Therapy Oncology Group protocols (1976-1985). Int J Radiat Oncol Biol Phys. 24:1992;441-449.
4. Iselin C.E., Box J.W., Vollmer R.T., et al. Surgical control of clinically localized prostate carcinoma is equivalent in African American and white males. Cancer. 83:1998;2353-2360.
5. Hart K.B., Porter A.T., Shamsa F., et al. The influence of race on the efficacy of curative radiation therapy for carcinoma of the prostate. Semin Urol Oncol. 16:1998;227-231.
6. Zagars G.K., Pollack A., Pettaway C.A. Prostate cancer in African American men: Outcome following radiation therapy with or without adjuvant androgen deprivation. Int J Radiat Oncol Biol Phys. 42:1998;517-523.
7. Lee L.N., Barnswell C., Torre T., et al. Prognostic significance of race on biochemical control in patients with localized prostate cancer treated with permanent brachytherapy: Multivariate and matched pair analysis. Int J Radiat Oncol Biol Phys. 53:2002;282-289.
8. Freeland S.J., Jalkut M., Dorey E., et al. Race is not an independent predictor of biochemical recurrence after radical prostatectomy in an equal access medical center. Urology. 56:2000;87-91.
9. Eastham J.A., Kattan M.W. Disease recurrence in black and white men undergoing radical prostatectomy for clinical stage T1-T2 prostate cancer. J Urol. 163:2000;143-145.
10. Sohayda C.J., Kupelian P.E., Altsman K.A., et al. Race as an independent predictor of outcome after localized treatment for localized prostate cancer. J Urol. 162:1999;1331-1336.
11. Connell P.P., Ignacio L., Haraf D., et al. Equivalent racial outcome after conformal radiotherapy for prostate cancer: A single departmental experience. J Clin Oncol. 19:2001;54-61.
12. Roach M., Lu J., Pilepich M., et al. Race and survival of men treated for prostate cancer on radiation therapy oncology group Phase III randomized trials. J Urol. 169:2003;245-250.
13. Johnstone P.A., Kane C.J., Sun L., et al. Effect of race on biochemical disease-free outcome in patients with prostate cancer treated with definitive radiation therapy in an equal access health care system: Radiation Oncology report of the Department of Defense Center for Prostate Disease Research. Radiology. 225:2002;420-426.
14. American Society for Therapeutic Radiology and Oncology Consensus Panel. Consensus statement: Guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys. 37:1997;1035-1041.
15. Zelefsky M.J., Leibel S.A., Gaudin P.B., et al. Dose escalation with three dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys. 41:1998;491-500.
16. 125I brachytherapy. Int J Radiat Oncol Biol Phys. 51:2001;31-40.
17. Critz F.A., Williams W.H., Holladay C.T., et al. Post-treatment PSA ≤0.2 ng/mL defines disease freedom after radiotherapy for prostate cancer using modern techniques. Urology. 54:1999;968-971.